このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

片頭痛の潜在的予防治療としての経鼻機械刺激(INMEST) (A-MI-01)

2026年11月2日 更新者:Abilion Medical Systems AB

片頭痛の予防的治療法としての鼻腔内機械的刺激(INMEST) - Walther Systemの安全性と性能を評価する前向き、無作為化、オープンラベル、遅延開始研究

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized 1:1 into two groups: Group A (early treatment) and Group B (delayed treatment). The study includes baseline assessments, in-clinic device training, and home-based self-administered treatments every second day for six weeks. The primary outcome is the change in monthly migraine days during the primary treatment comparison period. Secondary outcomes include headache days, migraine intensity, duration, rescue medication use, patient-reported outcomes, device compliance, and safety. The study will be conducted at one site in Sweden.

調査の概要

状態

積極的、募集していない

条件

研究の種類

介入

入学 (推定)

110

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age 18-65 years at the time of screening.

  2. The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject.

  3. Onset of migraine headache occurred before age 50.

  4. History of migraines for at least 1 year before screening.

  5. The study subject reports at least 8 monthly migraine days during the screening period.

  6. If subject is on a prophylactic migraine medication regimen:

    1. Reports stable medication regimen during the three months prior to screening.
    2. Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up.
  7. The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.

  8. Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study.

  9. Anticipated compliance with prescribed treatment and follow-up.

Exclusion Criteria:

  1. Subject unable to distinguish between migraine headaches and other headache types.
  2. Recently (12 months prior screening) undergone nasal or sinus surgery.
  3. Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation.
  4. Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s.
  5. Subject is pregnant or lactating or planning to get pregnant during the duration of the study.
  6. The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation.
  7. The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Group A - Early Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), then receive active treatment with the Walther System every second day for 6 weeks (weeks 5-10). The first treatment is performed under supervision at the clinic, and subsequent treatments are self-administered at home. Post-treatment assessments occur during weeks 11-14.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

他の名前:
  • ヴァルターシステム
アクティブコンパレータ:Group B - Delayed Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), followed by a 6-week no-treatment reference period (weeks 5-10). Active treatment with the Walther System is then administered every second day for 6 weeks (weeks 11-16), starting with an initial supervised treatment at the clinic. Post-treatment assessments occur during weeks 17-20.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

他の名前:
  • ヴァルターシステム

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Monthly Migraine Days
時間枠:Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Between-group comparison of the difference in mean change in monthly migraine days from the baseline assessment period (weeks 1-4) to Group A) Treatment performance period (weeks 7-10) and Group B) No treatment reference period (weeks 7-10).

Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

二次結果の測定

結果測定
メジャーの説明
時間枠
Mean change in monthly headache days
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change in monthly headache days from baseline.

Weeks 7-10
Mean change in migraine intensity
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change in migraine intensity from baseline.

Weeks 7-10
Mean change in duration of migraine attacks
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change in migraine attack duration (hours) from baseline.

Weeks 7-10
Proportion of attacks requiring rescue medication
時間枠:Weeks 7-10

Between-group comparison of the proportion of migraine attacks requiring rescue medication.

Weeks 7-10
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
時間枠:Weeks 7-10

Between-group comparison of the proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days.

Weeks 7-10
Mean change in PROMIS-PI SF-6b
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PROMIS-PI SF-6b scores. The raw scores are converted to standardized T-scores (range 0-100; mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Weeks 7-10
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change from baseline in MSQ scores. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Weeks 7-10
Mean change in Patient Global Impression of Severity (PGI-S)
時間枠:Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PGI-S scores. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Weeks 7-10
Mean change in monthly migraine days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity within each group. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours) within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores within each group. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores within each group. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores within each group. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly migraine days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity, pooled across both groups. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity."

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours), pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores, pooled across both groups. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores, pooled across both groups. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
時間枠:Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores, pooled across both groups. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of prescribed treatments completed
時間枠:Throughout the 6-week treatment period

Compliance based on device usage logs or participant-reported treatment diaries.

Throughout the 6-week treatment period
Adverse Events / Serious Adverse Events / Device Effects
時間枠:Through study completion (14 or 20 weeks, depending on treatment group)

Number of treatment-related AEs, SAEs, ADEs, SADEs, and Unanticipated SADEs for the Walther System.

Through study completion (14 or 20 weeks, depending on treatment group)
Device Deficiencies
時間枠:Throughout the 6-week treatment period

Number of device deficiencies for the Walther System.

Throughout the 6-week treatment period

その他の成果指標

結果測定
メジャーの説明
時間枠
Device usability and user experience (combined questionnaires)
時間枠:Throughout the 6-week treatment period

User-reported usability, ease of use, handling, and overall experience of the device during home use, assessed using two Device Usability Questionnaires. Questions include multiple 3- or 5-point scales, 0-10 scales, and yes/no responses. Higher scores indicate better usability or greater interest where applicable.

Throughout the 6-week treatment period
Symptom trends (Symptom Questionnaire)
時間枠:Throughout the 6-week treatment period

Changes in symptoms potentially related to autonomic nervous system function, assessed using the Symptom Questionnaire at Visits 1-5. The questionnaire includes multiple items with 0-6 and 0-3 ordinal scales, yes/no responses, and other response formats. Higher scores indicate more severe symptoms."

Throughout the 6-week treatment period

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jan-Erik Juto, PhD, MD

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年10月21日

一次修了 (推定)

2026年11月1日

研究の完了 (推定)

2026年11月1日

試験登録日

最初に提出

2025年11月18日

QC基準を満たした最初の提出物

2025年12月10日

最初の投稿 (実際)

2025年12月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • A-MI-01
  • CIV-25-05-052936 (レジストリ識別子:Swedish Clinical Trials Registry)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する